ABOUT ANTENGENE MANAGEMENT TEAM SCIENTIFIC ADVISORY BOARD BOARD OF DIRECTORS INVESTORS

INVESTORS

ABOUT Bristol-Myers Squibb

Bristol-Myers Squibb (BMS, NYSE: BMY) is an American pharmaceutical company founded in 1887, headquartered in New York City. BMS develops and manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. BMS also combines the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. In 2018, BMS realized a revenue of 22.5 billion USD and ranked 145 of Fortune 500 America.
In Nov. 2019, BMS completes the 75 billion USD acquisition of Celgene (Nasdaq: CELG) and becomes world's 4th largest pharmaceutical company.


ABOUT Qiming Venture Partners

Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. In 2016, Qiming raised a US healthcare fund, and set up Qiming US office in Seattle. Currently Qiming manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management.


ABOUT TF Capital

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. TF Capital's investment team has vast experience and resources in industry to assist their portfolio companies.


ABOUT TIGERMED

Headquartered in Hangzhou, Tigermed operates 33 subsidiaries with 95 offices across China and 11 others across the globe employing over 4000 Tigermed colleagues. To his day, we havesupported over 600 clients internationally inover 1500 clinical trials. Additionally,we are recognized as “The Innovative Clinical CRO” in China,owning to our meticulous reputation for quality and involvement inthe development ofover 160 innovative drugs.


ABOUT HUAGAI Capital

HG Healthcare Fund Management Co. Ltd., is a leading private equity fund management firm focused on the healthcare industry. Its fund I has over 1 billion RMB in assets under management. Fund II, which closed in May 2017 and raised over billions RMB, is focused on investing in mid-sized growth investments and buyouts in the healthcare sector. Investors (LP) of HG Healthcare Fund consist of 30+ healthcare public-listed companies.


ABOUT Boyu Capital

Boyu Capital is one of the largest private investment firms in China. With offices in Beijing and Hong Kong, Boyu has provided long-term capital and operational expertise to some of the best-managed and most innovative companies across the media/technology, healthcare, consumer/retail, and financial services industries.


ABOUT FountainVest

Founded in 2007, FountainVest Partners ("FountainVest") is one of the most established independent private equity firms in Asia. FountainVest focuses on long-term oriented investments in industry leaders, partnering closely with management teams to drive growth and create value in diversified areas, including strategy, operations, finance, and industry consolidation. FountainVest has completed a number of successful landmark investments in Asia, Europe, and the United States. Sectors of focus include Consumer, Media & Technology, Healthcare, Industrials, and Financial Services. FountainVest is backed by some of the largest sovereign wealth funds and public pensions plans around the world, with assets under management of close to USD 5.0 billion.


ABOUT WuXi AppTec

WuXi AppTec (603259.SH/2359.HK) is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."


ABOUT Taikang

Founded in 1996, Taikang is a leading insurance and financial service group in China. The company operates through three main businesses including insurance, asset management and health and elderly care. By end-2017, assets under management by Taikang exceed RMB1.2 trillion. With a major investment focus in healthcare, Taikang has invested in a number of companies such as Wuxi AppTec, Mindray Medical, and Innovent Biologics.